SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is the dominant topic, centered on Irth Capitals reported bid and a major U.S. franchisee joining the effort; traders are debating whether a deal will materialize, with no confirmed agreement in the discussion. The takeover hopes contrast with criticism of management and concern over weak sales, a dividend suspension, and the stocks steep decline.

TOSHI

A burst of trading volume and a recent rebound have fueled talk of a technical breakout and a possible short squeeze in TOSHI, with many holders buying dips and anticipating a move through resistance. Others point to repeated failed breakouts, weak price action, and broader crypto-market softness; talk of an upcoming announcement or listing remains speculative.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, news-unconfirmed XCN spike is driving attention, with traders reacting to a large candle and debating whether it marks a rebound or another brief pump-and-dump. Some are buying the dip and pointing to Bitcoins bounce, while skeptics say XCNs past spikes have quickly faded.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung cancer results for IMDELLTRA plus AstraZenecas IMFINZI, which reduced the risk of death in first-line extensive-stage small cell lung cancer, are driving attention. Traders see the findings as a potential growth catalyst and debate how much they could expand the drugs commercial role alongside established products such as Repatha.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and fears of disrupted oil supplies is driving attention to UCO. Traders are divided between following the bullish momentum and positioning for a pullback, with some noting that geopolitical headlines could quickly shift the oil trade.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention after reaching a new high as energy stocks outperform, with traders pointing to rising crude prices and supply risks tied to Middle East tensions and shipping disruptions. The conversation is broadly bullish on the breakout, though some traders warn the rally may be extended and question whether it can hold.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks attention centers on Phase 3 results for its partnership with Moderna: the personalized cancer vaccine added to Keytruda reduced melanoma recurrence or death risk, drawing interest in the oncology platform and potential commercial upside. Traders debate whether the results justify further gains, given high expectations, unapproved status, and questions about manufacturing complexity and expansion beyond melanoma.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 breast-cancer subgroup data presented at ESMO is drawing attention, with traders highlighting stronger progression-free survival and response results for gedatolisib combinations. Reactions are mixed: some see the findings as compelling, while others note the data builds on previously released topline results and say CELC still needs to demonstrate commercial uptake and revenue.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Holders are split between accumulating and anticipating a rebound, while skeptics point to weak momentum, limited utility, and the risk of further declines.

Anthropic

Anthropics anticipated blockbuster IPO is driving attention, with traders weighing rapid revenue growth against heavy compute commitments and reported losses. Some see a major AI-growth opportunity, while skeptics question whether the spending and intensifying competition can support the expected valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Grows By 22.2%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,204,555...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities...

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...

This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally

Equity

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00

Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...

These Stocks are Heating Up Fast

Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose.</li><li>The company expects to complete enrollment and report topline results from the trial by the end of 2026.</li><li>This comes just two weeks after the FDA approved Cort’s ovarian cancer treatment months ahead of schedule.</li></ul>Shares of Zentalis Pharmaceuticals (ZNTL) soared over 40% on Friday to their highest level since June 2024, after a bullish analyst call highlighted improved efficacy from a higher dose of its ovarian cancer drug while maintaining a comparable safety profile.Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating, according to The Fly. This implies a potential 56% upside from the stock’s current price. The firm cited the price target change to the increased confidence in the drug’s chances of success in platinum-resistant ovarian cancer.<h2 class="st-heading-2">Zentalis Picks 400 MG Dose For Future Trials</h2>On Thursday, Zentalis announced encouraging interim results from its DENALI Part 2a study of Azenosertib, an oral therapy, in platinum-resistant ovarian cancer, supporting the drug’s further late-stage development.The biotech firm selected the 400 mg once-daily dose (five days on, two days off) after it showed a clearly higher response rate than the 300 mg dose, while maintaining a similar safety profile. The 400 mg dose will now be used in the ongoing Phase 2 DENALI trial and the Phase 3 ASPENOVA study.Zentalis expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026.<h2 class="st-heading-2">FDA Approved Corcept’s Ovarian Cancer Drug Months Ahead Of PDUFA Date</h2>The results are crucial, as they allow Zentalis to move towards potential regulatory approval. Just two weeks earlier, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cort-stock-skyrockets-35-after-early-fda-nod-for-ovarian-cancer-drug/cZ3YMziRISr">approved</a> Corcept Therapeutics’ (CORT) ovarian cancer treatment.The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received treatment.Notably, the FDA’s decision came way ahead of schedule, as the therapy had been assigned a Prescription Drug User Fee Act (PDUFA) target date of July 11, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ZNTL">ZNTL</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the company’s valuation to explode seven to 10-fold if the drug is successful in monotherapy.<stembedurl>https://stocktwits.com/Lukey63/message/649876699</stembedurl>However, another user said the stock is overvalued, highlighting the company’s pipeline.<stembedurl>https://stocktwits.com/ScorpionScarlet/message/649934768</stembedurl>Year-to-date, the stock has shot up more than 370%.&nbsp;

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update

Corcept Therapeutics Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.21
Prev Close	$2.41
Open	$2.41
Dividend Yield	0.00%
50-Day Moving Average	$3.12
Beta	1.73
Avg. Volume	1.2M
PE Ratio	-1.13

52-Week High	$6.95
52-Week Low	$1.21
Market Capitalization	$209.22M
EPS (Annual)	-$1.91
Price to Book	1.10
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZNTL Fundamentals